COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 4 of 10 for:    ketamine | Sickle Cell Disease

Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02573714
Recruitment Status : Recruiting
First Posted : October 12, 2015
Last Update Posted : March 14, 2019
Carolinas Medical Center
Muhimbili National Hospital
Information provided by (Responsible Party):
Cameroon Baptist Convention Health

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019
Walker SE, Law S, DeAngelis C. Stability and compatibility of hydromorphone and ketamine in normal saline. Can J Hosp Pharm. 2001;54(3):191-199.
PedsQL Sickle Cell Disease Module, Version 3.0. 1998 JW Varni, Ph.D. (
Chien YW, Su KSE, Chang SF, Chapter 1: Anatomy and Physiology of the Nose. Nasal Systemic Drug Delivery, 1989. Dekker, New York: p. 1-26.,. "WHO | WHO Model Lists Of Essential Medicines." N.p., 2015. Web. 20 July 2015.
American Pain Society (1999a) Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. American Pain Society, Glenview, IL.
World Health Organisation, "Sickle cell anaemia. Agenda item 11.4," in 59th World Health Assembly, 27 May 2006, World Health Organisation, Geneva, Switzerland, 2006.

Publications automatically indexed to this study by Identifier (NCT Number):